Potential roles for ERK1/2 and β -arrestin 1 in the modulation of conditioned-fear 8 behavior 9 Our results suggest that SNC80 reduces conditioned fear through a mechanism that does not 1 0 involve β -arrestin 2 or G protein signaling. Therefore, we next hypothesized that the effect 1 1 may be mediated by β -arrestin 1 instead. However, SNC80 is known to induce severe the FPS response of SNC80 in this strain. Instead, we measured SNC80-induced ERK1/2 1 4 phosphorylation in the β -arrestin 1 KO mice. In comparison to WT mice ( Fig. 2g-k) , genetic 1 5 knockout of β -arrestin 1 prevented SNC80-mediated ERK1/2 phosphorylation in the dorsal 1 6 striatum and nucleus accumbens ( Fig. 6f-g; see Table S3 for one-way ANOVA and post-hoc 1 7 multiple comparison). In the amygdala and dorsal hippocampus of β -arrestin 1 KO mice, 1 8 SNC80 did increase ERK1/2 phosphorylation ( Fig. 6h-i) , but in contrast to the response 1 9
observed in WT mice, the activation was sustained for at least 30 minutes. Additionally, we 2 0 observed the same trend in the ventral hippocampus (Fig. 6j) , a region where we had 2 1 observed no δ OR agonist-mediated modulation of ERK1/2 in WT mice ( Fig. 2k and Fig. 6e ).
2
Thus, we hypothesized that the increased ERK1/2 in these regions is most likely a result of 2 3 seizure activity and not necessarily a result of δ OR-mediated effects. Here, we investigated the hypothesis that β -arrestin can modulate anxiety-and conditioned 3 fear-related behavior via downstream MAPK activation. By utilizing G protein-and β -4 arrestin-biased δ OR agonists together with β -arrestin-isoform selective knockout mice, we 5 discovered that G protein, β -arrestin 1, and β -arrestin 2 uniquely modulated ERK1/2 activity 6 resulting in differential outcomes in mouse models of anxiety/fear-related behavior. Our 7 results suggest that the reduction in anxiety-like behavior by SNC80 required the presence of 8 β -arrestin 2 as well as activation of ERK1/2. Distinctly in the dorsal hippocampus, we found 9 that ERK1/2 activation was β -arrestin 2-dependent ( Fig. 7a) . Notably, G protein-biased 1 0 signaling by TAN67 reduced ERK1/2 phosphorylation and was correlated with increased 1 1 FPS (Fig. 7b) . We found that SNC80-induced ERK1/2 activation in the nucleus accumbens 1 2 and the dorsal striatum required β -arrestin 1, which may be part of the mechanism for SNC80 1 3
to decrease FPS (Fig. 7c) .
4
Differential roles for β -arrestin isoforms in neuropsychiatric behavior. The β -arrestin 1 5
proteins were discovered in quick succession (Attramadal et al., 1992; Lohse et al., 1990 ). al., 2011). A potential reason for the preference of studying β -arrestin 2 may be that when the 2 0 β -arrestin 2 knockout mice were generated their first utilization was to highlight the proteins' (Chiang et al., 2016) ( Fig. S3) . Importantly, based on observations of enhanced anxiety-like 1 4
behavior in preproenkephalin KO mice, Leu-enkephalin has anxiolytic-like effects by itself 1 5 (Kung et al., 2010; Ragnauth et al., 2001) , which is in line with reports that the δOR 1 6
antagonist, naltrindole, is anxiogenic (Narita et al., 2006) . As a weak β -arrestin recruiter, 1 7
TAN67 would attenuate any baseline Leu-enkephalin-induced β -arrestin-mediated ERK 1 8 activity ( Fig. S3) . In contrast, because SNC80 is a stronger β -arrestin recruiter than Leu-1 9
enkephalin, it will elevate basal ERK1/2 activity produced by endogenous opioids. This 2 0 hypothesis would also explain why SNC80-induced ERK1/2 activation is quite variable and 2 1 produces on average only a two-fold increase. signaling for reduction in anxiety-like behavior, it is certainly possible that other GPCRs may 1 5 engage different intracellular signaling pathways following β -arrestin recruitment.
6
Fear-and anxiety-like behaviors rely on shared but distinct neural circuits. In our 1 7 study, we observed that β -arrestin 2-dependent ERK1/2 activity in the dorsal hippocampus 1 8
was associated with reduced anxiety-like behavior. Generally, CA1 regions of the ventral 1 9
hippocampus are associated with responding to contextually-conditioned anxiogenic stimuli hippocampus is connected to the anxiolytic-like effects of SNC80, agrees with a study 2 4
showing that intra-dorsal CA1 injection of the δOR antagonist naltrindole is anxiogenic overlapping, yet distinct, brain regions and circuits involved in memory retrieval, locomotion, approaches are necessary to assess the role of biased signaling pathways in the acquisition 1 7
and expression of conditioned fear-related behavior. but potentially even worsen these symptoms. Thus, our study results argue in favor of a 1 5 reassessment of drug development efforts that seek solely to identify G protein-biased drugs.
1 6
Instead, we propose that efforts should be directed towards the development of drugs with 1 7
finely tuned bias and, if possible, towards development of molecules that are biased against a 1 8 single β -arrestin isoform rather than both isoforms.
9
Conclusion. Overall, our results begin to reveal the complex-and context-specific 2 0 nature of GPCR biased signaling in modulation of fear-related and anxiety-like behavior.
1
These results expand our current understanding of therapeutic effects of β -arrestin signaling 2 2 in mood disorders, which ultimately may aid development of more efficacious pharmacological treatment options for these disorders. Abuse and Alcoholism (AA025368, AA026949, AA026675) and Drug Abuse (DA045897). The authors declare that the research was conducted in the absence of any commercial or 1 9
financial relationships that could be construed as a potential conflict of interest. brain sections with micropunctures of five specified brain regions for the Western blot decreased the basal ERK1/2 activity in all tested brain regions of wild-type mice.
1 4
Representative Western blot images are depicted next to each related bar graph. (f-j).
1 5
Systemic administration of SNC80 (20 mg/kg, i.p.) did not activate ERK1/2 in the striatal individual data points ± S.E.M.). arrestin isoform specific manner to modulate anxiety-and conditioned fear-related behaviors. hippocampus and amygdala (Localization) decreased anxiety-like behavior (a), whereas an 2 5 1 increase in conditioned fear-related behavior (Behavior) by TAN67 can be linked to 1 decreased ERK1/2 activity in all tested brain regions except for the ventral hippocampus (b).
2
Decreased FPS could not be correlated with G protein or β -arrestin 2 signaling, but may 3 involve β -arrestin -1 dependent ERK1/2 signaling in the dorsal striatum and nucleus 4 accumbens (c). and 85% saline. 20 mg/kg SNC80 was subcutaneously administered 30 minutes prior to the 1 7 tests in Fig. 1d-g, Fig. 4b and Fig. S1 , and 50 mg/kg SL327 was subcutaneously 1 8 administered 60 minutes prior to the administration of SNC80 for Fig. 4. For Fig. 2-6 based on our previous study (van Rijn et al., 2010) and our preliminary studies (data not 2 2 shown). Separate batches of mice with no prior history of drug injection were used for the 2 3
brain collection and behavioral tests to test earlier time-points of ERK1/2 signaling (such as 2 4 10 minutes). Elevated-plus maze test The elevated-plus maze test was performed as previously described 1 (van Rijn et al., 2010) . Mice were allowed to explore the maze for 5 minutes, and arm entries 2 and time spent in each arm were recorded with a camera positioned above the maze. (Kinder Scientific, Poway, CA). Mice groups were counterbalanced, such that no significant 1 6 differences between startle reflexes were observed between groups (Fig. S4) were first sliced as coronal sections (1.5-2.0 mm) with a brain matrix (#RBMS-205C, Kent 1 scientific, Torrington, CT), and then flash-frozen in dry-ice-chilled 2-methylbutane (-40 °C) 2 (#03551-4, Fisher Scientific). Regions of interest were collected from these slices using a 1 3 mm biopsy micropunch (#15110-10, Miltex, Plainsboro, NJ) as follows: dorsal striatum and 4 nucleus accumbens (A/P: +0.5 mm to +1.5 mm), dorsal hippocampus and amygdala (A/P: -1 5 mm to -2 mm), and ventral hippocampus (A/P: -2 mm to -4 mm) (Paxinos and Franklin, VA) were cultured as recommended by the manufacturer and maintained at 37° C/5 % CO 2 .
0
Cells were seeded in a clear 6 well plate (Corning TM , Thermo Fisher Scientific) with 250,000 2 1 cells/2 mL/well. On the following day, all growth media was aspirated and changed into 1 2 2 mL serum-free Opti-MEM (#31985070, Gibco®, Thermo Fisher Scientific). The next day, 2 3 cells were challenged with 10 µM drugs (SNC80) for a specific duration (0, 3, 6, 20, and 60 2 4 minutes). All drugs were diluted in Opti-MEM prior to administration. The media was 2 5 2 5 aspirated following the challenge and 100 µL RIPA buffer was added to collect the samples 1 on ice. Using cell scrapers (#353089, Thermo Fisher Scientific), all samples were dislodged 2 from the 6 well plate, collected and stored at -30° C until usage. For the Western blot, the 3 collected samples were quantified with the Bradford assay and samples were prepared with 4 4
x Laemmli and boiled at 95° C for 5 minutes. The CHO-δOR-βArr2 cells were also used to 5 measure β -arrestin recruitment using the DiscoverX PathHunter Assay as previously used in the study are listed in Table S4 . Prepared samples were scanned using the LiCor 1 3
Odyssey® CLx Scanner (Li-Cor, Lincoln, NE). By utilizing the Li-Cor secondary antibodies, 1 4
we were able to detect the MAPK, pMAPK, and α -Tubulin on the same blot without the need 1 5 of stripping/reblotting. In the same membrane, each band was cut based on their size. For 1 6 instance, ERK1/2 and pERK1/2 bands were collected around 42/44 kDa and α -Tubulin band 1 7
was collected around 50 kDa in the same membrane. For statistical analysis, we normalized 1 8
the pMAPK/MAPK ratio to α -Tubulin in case drug treatment changed ERK1/2 levels.
9
Preparation of tissue for immunofluorescence To preserve the intact ERK1/2 activity in 2 0 vivo for fluorescence microscopy, mice were transcardially perfused before isolation of brain 2 1 tissue. Thirty minutes prior to transcardiac perfusion, mice were administered with 100/10 2 2 mg/kg Ketamine/Xylazine. Ten minutes prior to perfusion, 20 mg/kg SNC80 (i.p.) or a 2 3 corresponding volume of saline was administered to the mice. Mice were then perfused with 2 4
